Frances R Levin1, Adam Bisaga1, Maria A Sullivan2,3, Arthur Robin Williams1, Kathryn Cates-Wessel4. 1. New York State Psychiatric Institute & Department of Psychiatry, Columbia University, New York, New York. 2. Department of Psychiatry, Columbia University, New York, New York. 3. Alkermes, Inc., Waltham, Massachusetts. 4. American Academy of Addiction Psychiatry, East Providence, Rhode Island.
Abstract
BACKGROUND AND OBJECTIVES: The Providers' Clinical Support System for Medication Assisted Treatment (PCSS-MAT) initiative focuses on training and mentoring health professionals in the treatment of opioid use disorders (OUD) using pharmacological strategies. Led by the American Academy of Addiction Psychiatry (AAAP), PCSS-MAT is a consortium representing four of the five national professional organizations authorized by DATA 2,000-AAAP, American Osteopathic Academy of Addiction Medicine, American Psychiatric Association, and American Society of Addiction Medicine. DATA organizations are authorized to train physicians to prescribe buprenorphine for OUD treatment. The primary aim of PCSS-MAT is to substantially increase evidence-based practices with medications for OUD. METHODS: This review describes the development of PCSS-MAT, an ongoing national initiative funded by the Substance Abuse and Mental Health Services Administration (SAMHSA), to address the training needs posed by this critical public health problem. Core initiatives include: (1) Training and mentoring activities for primary care physicians; (2) Outreach to multidisciplinary professional organizations, (3) Creating a resource portal for families, patients, and communities for OUD treatment. RESULTS: Educational outreach to providers addresses the needs of patients with OUD and common co-occurring psychiatric and medical disorders. DISCUSSION AND CONCLUSIONS: The overall scope of PCSS-MAT is to increase access to evidence-based treatment of substance use disorders as a public health priority. Recently enacted legislation requires office-based opioid treatment programs to offer all Food and Drug Administration-approved (FDA) forms of MAT. SCIENTIFIC SIGNIFICANCE: Working with health care providers to effectively deliver MAT is key to integrating behavioral and physical medicine. (Am J Addict 2016;25:603-609).
BACKGROUND AND OBJECTIVES: The Providers' Clinical Support System for Medication Assisted Treatment (PCSS-MAT) initiative focuses on training and mentoring health professionals in the treatment of opioid use disorders (OUD) using pharmacological strategies. Led by the American Academy of Addiction Psychiatry (AAAP), PCSS-MAT is a consortium representing four of the five national professional organizations authorized by DATA 2,000-AAAP, American Osteopathic Academy of Addiction Medicine, American Psychiatric Association, and American Society of Addiction Medicine. DATA organizations are authorized to train physicians to prescribe buprenorphine for OUD treatment. The primary aim of PCSS-MAT is to substantially increase evidence-based practices with medications for OUD. METHODS: This review describes the development of PCSS-MAT, an ongoing national initiative funded by the Substance Abuse and Mental Health Services Administration (SAMHSA), to address the training needs posed by this critical public health problem. Core initiatives include: (1) Training and mentoring activities for primary care physicians; (2) Outreach to multidisciplinary professional organizations, (3) Creating a resource portal for families, patients, and communities for OUD treatment. RESULTS: Educational outreach to providers addresses the needs of patients with OUD and common co-occurring psychiatric and medical disorders. DISCUSSION AND CONCLUSIONS: The overall scope of PCSS-MAT is to increase access to evidence-based treatment of substance use disorders as a public health priority. Recently enacted legislation requires office-based opioid treatment programs to offer all Food and Drug Administration-approved (FDA) forms of MAT. SCIENTIFIC SIGNIFICANCE: Working with health care providers to effectively deliver MAT is key to integrating behavioral and physical medicine. (Am J Addict 2016;25:603-609).
Authors: Stefan G Kertesz; Yulia Khodneva; Joshua Richman; Jalie A Tucker; Monika M Safford; Bobby Jones; Joseph Schumacher; Mark J Pletcher Journal: J Gen Intern Med Date: 2012-01-25 Impact factor: 5.128
Authors: M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor Journal: Health Technol Assess Date: 2007-03 Impact factor: 4.014
Authors: James E Egan; Paul Casadonte; Tracy Gartenmann; Judith Martin; Elinore F McCance-Katz; Julie Netherland; John A Renner; Linda Weiss; Andrew J Saxon; David A Fiellin Journal: J Gen Intern Med Date: 2010-05-11 Impact factor: 5.128
Authors: Cindy Parks Thomas; Catherine Anne Fullerton; Meelee Kim; Leslie Montejano; D Russell Lyman; Richard H Dougherty; Allen S Daniels; Sushmita Shoma Ghose; Miriam E Delphin-Rittmon Journal: Psychiatr Serv Date: 2014-02-01 Impact factor: 3.084
Authors: Marc Fishman; Kevin Wenzel; Jennifer Scodes; Martina Pavlicova; Joshua D Lee; John Rotrosen; Edward Nunes Journal: J Adolesc Health Date: 2020-08-29 Impact factor: 5.012
Authors: Sarah Sweeney; Kelly Coble; Elizabeth Connors; Kathleen Rebbert-Franklin; Christopher Welsh; Eric Weintraub Journal: Subst Abus Date: 2020-08-19 Impact factor: 3.716
Authors: Jennifer McNeely; Daniel Schatz; Mark Olfson; Noa Appleton; Arthur Robin Williams Journal: Psychiatr Serv Date: 2021-09-15 Impact factor: 4.157
Authors: Elizabeth C Saunders; Sarah K Moore; Olivia Walsh; Stephen A Metcalf; Alan J Budney; Patricia Cavazos-Rehg; Emily Scherer; Lisa A Marsch Journal: Addict Sci Clin Pract Date: 2021-01-27
Authors: Christine A Schalkoff; Emma L Richard; Hannah M Piscalko; Adams L Sibley; Daniel L Brook; Kathryn E Lancaster; William C Miller; Vivian F Go Journal: Subst Use Misuse Date: 2021-03-07 Impact factor: 2.164
Authors: Marc Fishman; Kevin Wenzel; Jennifer Scodes; Martina Pavlicova; Aimee N C Campbell; John Rotrosen; Edward Nunes Journal: Am J Addict Date: 2021-06-01